In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Recipe for Acquisition: the Esperion Strategy

Executive Summary

Though one key ingredient is luck, exit-by-M&A can be planned, as the Esperion-Pfizer transaction shows. Focusing on a single underappreciated pathway and eschewing discovery, Esperion put together, very inexpensively and very quickly, an in-licensed portfolio of related compounds. By doing so, Esperion minimized the chances it would find itself competing against an improved follow-on should it prove the value of its mechanism of action. Likewise, once it had reached some clinical proof of principle, its strategy positioned it either for a major multi-product deal or, even more likely, an acquisition-with Pfizer's $1.3 billion takeover the eventual outcome.
Advertisement

Related Content

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2008
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2008
Can Out-Partnering Help Vault Pfizer Over the "Second Cliff"?
Esperion, Again: Pfizer's First Spin-Out's Familiar Look
Esperion, Again: Pfizer's First Spin-Out's Familiar Look
The A-List: 2006's Trend-Shaping Series A Financings
Cerenis: Aspiring to Esperion?
Pfizer-Vicuron: Fill Pipeline, Minimize R&D Expense
Torcetrapib: Biomarker for the Big Pharma Business Model
Big Pharma's Large Molecule Challenge

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002212

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel